Angiogenesisdriven

Angiogenesisdriven is a term used to describe biological processes, disease states, or research programs in which angiogenesis—the growth of new blood vessels from existing vasculature—acts as the central driving force behind growth, progression, or regeneration.

In these contexts, endothelial cell proliferation, sprouting, and vessel remodeling are coordinated by pro-angiogenic signals such as vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and angiopoietins, with counterbalancing anti-angiogenic cues. Notch signaling and extracellular matrix remodeling also regulate sprout guidance, branching, and vessel maturation. The result is the formation of new perfused vasculature that can alter tissue oxygenation and nutrient delivery.

Examples of angiogenesisdriven scenarios include tumor progression, where neovascularization supports oncogenic growth and potential metastasis; wound healing and tissue regeneration, where new vessels restore perfusion after injury; and embryonic development or placental formation, where orderly vascularization is essential for proper organ growth and function.

Clinically and in research, angiogenesisdriven concepts inform strategies to modulate blood vessel growth. Anti-angiogenic approaches aim to slow or halt cancer progression, while pro-angiogenic or pro-vascular therapies seek to enhance perfusion in ischemic tissues or promote tissue integration in regenerative medicine. Assessment commonly uses measures of microvessel density, imaging of perfused vasculature, and biomarkers linked to VEGF signaling.

Challenges include abnormal tumor vasculature that impedes drug delivery, adaptive resistance to anti-angiogenic therapies, and the need to balance vessel growth with tissue stability. Ongoing work focuses on context-dependent, controlled modulation of angiogenesis to optimize outcomes.